PURPOSE: To evaluate the use of transpupillary thermotherapy (TTT) for myopic choroidal neovascularization (CNV) retrospectively in a case series. METHODS: Ten consecutive patients with CNV secondary to high myopia were treated with TTT and followed-up for 18.3 +/- 7.1 months (range: 12-30 months). An activity scoring (AS) scheme based on CNV size, central foveal thickness as determined by optical coherence tomography (OCT), amount of subretinal hemorrhage, and fluorescein angiography (FA) staining characteristics was developed to assess the response to treatment. The main outcome measures were AS and visual acuity (VA). RESULTS: There was no significant loss or gain in VA, and the lesions stabilized in all eyes. FA revealed late staining typical of CNV scarring, and the amount of central foveal thickness decreased in all eyes, as determined by OCT. The mean AS at 3, 6, and 12 months and at the final visit were significantly lower than the preoperative AS (P<0.05). No complication occurred during or after treatment. CONCLUSION: A scheme for evaluating overall CNV activity may be useful tool for assessing the response of patients to TTT. TTT seems to stabilize myopic CNVs both clinically and as revealed by angiography, with a significant decrease in the activity of lesions. Longer term results are required to evaluate the stabilizing effect of TTT in myopic CNV.
PURPOSE: To evaluate the use of transpupillary thermotherapy (TTT) for myopic choroidal neovascularization (CNV) retrospectively in a case series. METHODS: Ten consecutive patients with CNV secondary to high myopia were treated with TTT and followed-up for 18.3 +/- 7.1 months (range: 12-30 months). An activity scoring (AS) scheme based on CNV size, central foveal thickness as determined by optical coherence tomography (OCT), amount of subretinal hemorrhage, and fluorescein angiography (FA) staining characteristics was developed to assess the response to treatment. The main outcome measures were AS and visual acuity (VA). RESULTS: There was no significant loss or gain in VA, and the lesions stabilized in all eyes. FA revealed late staining typical of CNV scarring, and the amount of central foveal thickness decreased in all eyes, as determined by OCT. The mean AS at 3, 6, and 12 months and at the final visit were significantly lower than the preoperative AS (P<0.05). No complication occurred during or after treatment. CONCLUSION: A scheme for evaluating overall CNV activity may be useful tool for assessing the response of patients to TTT. TTT seems to stabilize myopic CNVs both clinically and as revealed by angiography, with a significant decrease in the activity of lesions. Longer term results are required to evaluate the stabilizing effect of TTT in myopic CNV.
Authors: Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams Journal: Ophthalmology Date: 2003-04 Impact factor: 12.079
Authors: H Tabandeh; H W Flynn; I U Scott; M L Lewis; P J Rosenfeld; F Rodriguez; A Rodriguez; L J Singerman; J Schiffman Journal: Ophthalmology Date: 1999-11 Impact factor: 12.079
Authors: F Bottoni; E Perego; P Airaghi; M Cigada; S Ortolina; G Carlevaro; V De Molfetta Journal: Graefes Arch Clin Exp Ophthalmol Date: 1999-07 Impact factor: 3.117